Ligand (LGND), Glaxo (GSK) Receive FDA Approval for PROMACTA in HCV Patients
- Shares jump on tech boost; fragile yen on intervention watch
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- Oil prices steady after rallying on US stock decline, business data
- Yen on the brink, but Tesla pulls back
- Dollar recovers from PMI slump, yen closes in on 155 per dollar
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Wolfe Research Downgrades Warner Brothers Discovery (WBD) to Underperform, 'out of concern that an incipient advertising downturn put guidance at risk'
- Wall Street closes higher as investors digest earnings, megacap outlook
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
Ligand Pharma (LGND) shares resume trading; shares up ~8%
November 19, 2012 9:45 AM ESTLigand Pharma (NASDAQ: LGND) shares resume trading. The stock is up 9 percent at the start.... More
Ligand Pharmaceuticals (LGND) halted, news pending
November 19, 2012 8:56 AM ESTLigand Pharmaceuticals (Nasdaq: LGND) halted, news pending... More